Literature DB >> 27465895

The Safety of Ovarian Preservation in Early-Stage Adenocarcinoma Compared With Squamous Cell Carcinoma of Uterine Cervix: A Systematic Review and Meta-Analysis of Observational Studies.

Xiao-Bing Jiao1, Jun Hu, Li-Rong Zhu.   

Abstract

OBJECTIVE: The aim of this study was to compare the incidence of ovarian metastasis (OM) in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) in early-stage cervical cancer and evaluate the safety of ovarian preservation in early-stage ADC.
METHODS: To perform a meta-analysis to compare the incidence of OM between early-stage ADC and SCC, we searched PubMed, EMBASE, and Cochrane for observational studies that compared it with pathological evidence after radical hysterectomy and oophorectomy. Odds ratios with 95% confidence intervals were calculated with a fixed effects model. We also found a few articles evaluating the oncological prognosis of patients with ovarian preservation to perform a systematic review.
RESULTS: A total of 5 studies were included in the meta-analyses. The incidence of OM of patients with early-stage ADC and SCC were 2% and 0.4%, respectively (odds ratio, 5.27; 95% confidence interval, 2.14-13.45). In 1427 patients with ADC or SCC of the cervix FIGO stage (CIS-IIA) who underwent hysterectomy, no ovarian recurrences were observed after unilateral or bilateral ovarian preservation in ADC patients in the follow-up (30-68 months); however, 15 patients with SCC developed pelvic recurrence.
CONCLUSIONS: Although the incidence of OM was higher in early-stage ADC than SCC according to ovarian pathology, it might be relatively safe to perform ovarian preservation with early-stage ADC because of low ovarian recurrence rate in short-term follow-ups.

Entities:  

Mesh:

Year:  2016        PMID: 27465895     DOI: 10.1097/IGC.0000000000000780

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  8 in total

1.  A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.

Authors:  Xiuzhen Xie; Kun Song; Baoxia Cui; Jie Jiang; Xingsheng Yang; Beihua Kong
Journal:  Int J Clin Oncol       Date:  2018-01-03       Impact factor: 3.402

2.  Influence of ovarian-sparing surgery and ovariectomy on prognosis in early cervical adenocarcinoma: a systematic review and meta-analysis.

Authors:  Jiangxin Sheng; Yunhua Yi; Jichan Nie
Journal:  Gland Surg       Date:  2022-06

3.  Ovarian conservation for young women with clinical stage IB-IIB cervical cancer in Japan.

Authors:  Koji Matsuo; Muneaki Shimada; Mikio Mikami
Journal:  J Gynecol Oncol       Date:  2017-07       Impact factor: 4.401

4.  Safety and Prognostic Impacts of Ovarian Preservation during Radical Hysterectomy for Early-Stage Adenocarcinoma and Adenosquamous Cervical Cancer.

Authors:  Arisa Theplib; Jitti Hanprasertpong; Kittinun Leetanaporn
Journal:  Biomed Res Int       Date:  2020-11-12       Impact factor: 3.411

5.  SOX1 and PAX1 Are Hypermethylated in Cervical Adenocarcinoma and Associated with Better Prognosis.

Authors:  Zitong Zhao; Xiaoye Zhang; Xueheng Zhao; Jingting Cai; Na-Yi Yuan Wu; Jing Wang
Journal:  Biomed Res Int       Date:  2020-12-07       Impact factor: 3.411

6.  Large Conization-Retrospective Monocentric Results for Fertility Preservation in Young Women with Early Stage Cervical Cancer.

Authors:  Christos Tsaousidis; Bernhard Kraemer; Stefan Kommoss; Andreas Hartkopf; Sara Brucker; Katrin Neis; Juergen Andress; Felix Neis
Journal:  Reprod Sci       Date:  2021-11-29       Impact factor: 3.060

Review 7.  Fertility-Sparing Treatment for Early-Stage Cervical, Ovarian, and Endometrial Malignancies.

Authors:  Roni Nitecki; Terri Woodard; J Alejandro Rauh-Hain
Journal:  Obstet Gynecol       Date:  2020-12       Impact factor: 7.623

8.  Ovarian metastasis in women with cervical carcinoma in stages IA to IIB: A systematic review and meta-analysis.

Authors:  Yu Fan; Meng-Yao Wang; Yi Mu; Si-Ping Mo; Ai Zheng; Jin-Ke Li
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.